Unknown

Dataset Information

0

Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC.


ABSTRACT: Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as treatment for Coronavirus Disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200mL of CCP with a Spike protein IgG titer ?1:2,430 (median 1:47,385) within 72 hours of admission to propensity score-matched controls cared for at a medical center in the Bronx, between April 13 to May 4, 2020. Matching criteria for controls were age, sex, body mass index, race, ethnicity, comorbidities, week of admission, oxygen requirement, D-dimer, lymphocyte counts, corticosteroids, and anticoagulation use. There was no difference in mortality or oxygenation between CCP recipients and controls at day 28. When stratified by age, compared to matched controls, CCP recipients <65 years had 4-fold lower mortality and 4-fold lower deterioration in oxygenation or mortality at day 28. For CCP recipients, pre-transfusion Spike protein IgG, IgM and IgA titers were associated with mortality at day 28 in univariate analyses. No adverse effects of CCP were observed. Our results suggest CCP may be beneficial for hospitalized patients <65 years, but data from controlled trials is needed to validate this finding and establish the effect of ageing on CCP efficacy.

SUBMITTER: Yoon HA 

PROVIDER: S-EPMC7724683 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Treatment of Severe COVID-19 with Convalescent Plasma in the Bronx, NYC.

Yoon Hyun Ah HA   Bartash Rachel R   Gendlina Inessa I   Rivera Johanna J   Nakouzi Antonio A   Bortz Robert H RH   Wirchnianski Ariel S AS   Paroder Monika M   Fehn Karen K   Serrano-Rahman Leana L   Babb Rachelle R   Sarwar Uzma N UN   Haslwanter Denise D   Laudermilch Ethan E   Florez Catalina C   Dieterle M Eugenia ME   Jangra Rohit K RK   Fels J Maximilian JM   Tong Karen K   Mariano Margarette C MC   Vergnolle Olivia O   Georgiev George I GI   Herrera Natalia G NG   Malonis Ryan J RJ   Quiroz Jose A JA   Morano Nicholas C NC   Krause Gregory J GJ   Sweeney Joseph M JM   Cowman Kelsie K   Allen Stephanie S   Annam Jayabhargav J   Applebaum Ariella A   Barboto Daniel D   Khokhar Ahmed A   Lally Brianna J BJ   Lee Audrey A   Lee Max M   Malaviya Avinash A   Sample Reise R   Yang Xiuyi A XA   Li Yang Y   Ruiz Rafael R   Thota Raja R   Barnhill Jason J   Goldstein Doctor Y DY   Uehlinger Joan J   Garforth Scott J SJ   Almo Steven C SC   Lai Jonathan R JR   Gil Morayma Reyes MR   Fox Amy S AS   Chandran Kartik K   Wang Tao T   Daily Johanna P JP   Pirofski Liise-Anne LA  

medRxiv : the preprint server for health sciences 20201204


Convalescent plasma with severe acute respiratory disease coronavirus 2 (SARS-CoV-2) antibodies (CCP) may hold promise as treatment for Coronavirus Disease 2019 (COVID-19). We compared the mortality and clinical outcome of patients with COVID-19 who received 200mL of CCP with a Spike protein IgG titer ≥1:2,430 (median 1:47,385) within 72 hours of admission to propensity score-matched controls cared for at a medical center in the Bronx, between April 13 to May 4, 2020. Matching criteria for contr  ...[more]

Similar Datasets

| S-EPMC7934933 | biostudies-literature
| S-EPMC7196837 | biostudies-literature
| S-EPMC7722692 | biostudies-literature
| S-EPMC8598255 | biostudies-literature
2022-04-01 | GSE198257 | GEO
| S-EPMC7251400 | biostudies-literature
| S-EPMC8354811 | biostudies-literature
| S-EPMC7262027 | biostudies-literature
| S-EPMC7327024 | biostudies-literature
| S-EPMC7717772 | biostudies-literature